Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer

Details for Australian Patent Application No. 2006227880 (hide)

Owner Pfizer Products Inc.

Inventors Baum, Charles Michael; Gomez-Navarro, Jesus

Agent Allens Arthur Robinson

Pub. Number AU-A-2006227880

PCT Pub. Number WO2006/101692

Priority 60/664,653 23.03.05 US

Filing date 3 March 2006

Wipo publication date 28 September 2006

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

13 September 2007 PCT application entered the National Phase

  PCT publication WO2006/101692 Priority application(s): WO2006/101692

29 September 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006227884-Saw blade with cutting depth gauge

2006227879-Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy